For patients searching for new drugs for melanoma recurrence, a Phase 3 clinical trial has reached an important milestone. Intismeran autogene, a personalized mRNA-based cancer therapy, combined with Keytruda (pembrolizumab) significantly improved recurrence-free survival and distant metastasis-free survival compared with Keytruda alone in patients with high-risk melanoma that had been completely removed with surgery.
Merck and Moderna announced in August 2026 that the Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS). The trial included patients with completely resected stage IIB, IIC, III, and IV cutaneous melanoma.
This is the first positive Phase 3 trial of an individualized neoantigen therapy and an mRNA-based cancer therapy. However, intismeran autogene remains investigational and is not yet an approved melanoma treatment. Full Phase 3 results have not yet been presented, and the companies plan to discuss regulatory submissions with health authorities.
THE BASICS: Intismeran autogene is a personalized mRNA therapy created using information from an individual patient's tumor. In the Phase 3 INTerpath-001 trial, adding intismeran to Keytruda after melanoma surgery significantly improved the amount of time patients remained free from recurrence and distant metastasis compared with Keytruda alone.
What did the Phase 3 melanoma clinical trial find?
INTerpath-001 is a randomized Phase 3 trial evaluating intismeran autogene plus Keytruda as adjuvant therapy for patients with high-risk melanoma following complete surgical removal of their cancer.
The trial enrolled 1,137 patients with completely resected stage IIB, IIC, III, or IV cutaneous melanoma. Patients had not previously received systemic therapy for their melanoma.
Patients were randomly assigned to receive intismeran plus Keytruda or Keytruda alone. At a planned interim analysis, the combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival.
The trial is continuing to evaluate additional outcomes, including overall survival, safety, tolerability, and quality of life.
What does recurrence-free survival mean for melanoma patients?
Recurrence-free survival measures how long a patient remains alive without melanoma returning after treatment.
Melanoma can sometimes return near the site of the original tumor, in nearby lymph nodes, or in distant areas of the body. Treatments given after surgery are intended to reduce the likelihood that remaining melanoma cells will lead to recurrent disease.
Distant metastasis-free survival measures the amount of time before cancer spreads to a distant part of the body or the patient dies. Improving both outcomes is especially important for patients with melanoma at high risk of recurrence.
What is intismeran autogene?
Intismeran autogene, previously known as V940 or mRNA-4157, is an investigational individualized neoantigen therapy. It uses mRNA technology to help the immune system recognize specific characteristics of a patient's cancer.
Unlike a traditional vaccine designed to prevent an infection, intismeran is created individually for each patient after melanoma has already been diagnosed and surgically removed.
Scientists analyze genetic information from a sample of the patient's tumor to identify mutations that could create abnormal proteins called neoantigens. A personalized synthetic mRNA therapy is then designed to encode up to 34 of these neoantigens.
After the therapy is administered, the goal is to help the immune system recognize these cancer-specific targets and generate T-cell responses against remaining melanoma cells.
How is the personalized mRNA cancer therapy made?
Creating intismeran requires information from each patient's tumor, which is why it differs from a medication manufactured identically for every patient.
The process begins with a tumor sample collected during surgery. The tumor is analyzed to identify its unique mutational signature, sometimes described as its molecular “fingerprint.”
Scientists then select neoantigens that may be useful targets for the immune system. Synthetic mRNA encoding up to 34 of those neoantigens is created specifically for that patient.
The mRNA is delivered in lipid nanoparticles, which help protect the genetic material and allow it to enter cells. The resulting neoantigens are presented to the immune system, with the goal of training T cells to recognize cancer cells carrying those targets.
What is Keytruda immunotherapy?
Keytruda, also known as pembrolizumab, is an immunotherapy medication called a PD-1 immune checkpoint inhibitor.
Cancer cells can use checkpoint pathways to make it harder for immune cells to recognize and attack them. Keytruda blocks PD-1, helping restore the ability of T cells to recognize and attack certain cancer cells.
Pembrolizumab is already used to treat melanoma and many other cancers. Depending on a patient's melanoma stage and clinical situation, it may be used before surgery, after surgery, or for advanced disease.
Why combine an mRNA therapy with Keytruda immunotherapy?
The two therapies are designed to support the immune response in different ways.
Intismeran is designed to train and activate an immune response against neoantigens specific to an individual patient's tumor. Keytruda blocks an immune checkpoint that cancer cells can use to avoid attack.
Researchers are studying whether combining these approaches can produce a stronger and more effective immune response against microscopic melanoma cells that may remain after surgery.
The positive Phase 3 results suggest the combination can reduce the risk of melanoma returning or spreading compared with Keytruda alone in the patients studied.
How was intismeran + Keytruda given in the Phase 3 trial?
Patients assigned to the combination received intismeran at a dose of 1 mg every three weeks for up to nine doses.
Keytruda was given at 400 mg every six weeks for up to nine cycles, or approximately one year. Patients in the comparison group received Keytruda alone.
Treatment continued until melanoma recurrence, unacceptable toxicity, or completion of the planned treatment period.
Which stage II melanoma patients were included?
The Phase 3 trial included patients with completely resected stage II melanoma at stages IIB and IIC.
Stage II melanomas have grown deeper into the skin or have other features associated with a greater risk of recurrence but have not been found in nearby lymph nodes or distant organs.
Patients with IIC melanoma have particularly high-risk features. After surgery, some patients with stage IIB or IIC melanoma may be offered adjuvant immunotherapy to reduce the risk that melanoma returns.
What does the trial mean for stage III melanoma?
Stage III melanoma has generally spread beyond the original melanoma to nearby lymph nodes, lymphatic channels, or nearby areas of skin, depending on the specific stage.
Melanoma staging is based on several factors, including features of the primary melanoma and whether cancer is present in lymph nodes or other parts of the body.
A sentinel lymph node biopsy may be used in certain patients to determine whether melanoma has spread to nearby lymph nodes. The results of a sentinel lymph node biopsy, along with the pathology from the original melanoma, can help determine the stage and guide treatment decisions.
For patients with stage III melanoma that can be completely removed, additional treatment after surgery may be recommended because of the risk that microscopic cancer cells remain elsewhere in the body.
What about stage IV melanoma?
Stage IV melanoma means melanoma has spread to a distant part of the body. However, the patients with stage IV disease enrolled in INTerpath-001 had melanoma that could be completely surgically removed before entering the study.
This is different from patients who currently have unresectable or metastatic melanoma that remains visible or measurable in the body.
The trial therefore should not be interpreted as showing that intismeran plus Keytruda is an established treatment for all patients with metastatic melanoma.
What is adjuvant therapy for melanoma?
Adjuvant therapy is additional cancer treatment given after the primary treatment, usually surgery, to lower the risk that cancer returns.
Even when all visible melanoma is removed, microscopic melanoma cells may remain somewhere in the body. These cells can potentially grow and cause recurrence later.
For patients at higher risk of recurrence, adjuvant treatment may include immunotherapy or, for certain melanomas with specific BRAF gene changes, targeted therapy.
Intismeran plus Keytruda is being studied as another potential adjuvant treatment approach.
How do doctors decide on melanoma treatment after surgery?
Treatment decisions depend on several factors, including melanoma staging, the tumor's location and characteristics, lymph node involvement, molecular findings, previous treatments, and the patient's overall health.
A biopsy and detailed pathology report provide information needed to confirm the melanoma diagnosis and determine important features of the tumor.
For some patients, a sentinel lymph node biopsy helps determine whether melanoma has spread beyond the original site. Imaging and other tests may also be used when appropriate.
A medical oncology team can then discuss whether surveillance alone or additional systemic treatment is recommended.
What are the current melanoma treatment options?
Melanoma treatment options vary considerably depending on the stage of the disease.
Surgery is often the first treatment for melanoma that can be completely removed. Some patients with higher-risk melanoma may then receive immunotherapy or targeted therapy as additional treatment.
Immunotherapy treatments include immune checkpoint inhibitors such as pembrolizumab and nivolumab. Nivolumab or pembrolizumab may be used in several melanoma treatment settings.
For melanomas with certain gene changes, particularly a BRAF V600 mutation, targeted therapy may also be an option. These medications target specific molecular pathways that help melanoma cells grow.
For advanced melanoma, other treatments may be considered depending on the individual situation. The appropriate treatment should be determined with a melanoma specialist or medical oncology team.
Is intismeran a standard melanoma treatment yet?
No. Intismeran autogene remains investigational.
The Phase 3 trial reaching its primary endpoint is an important step, but it does not mean the therapy has already been approved or has become a standard treatment for melanoma.
Merck and Moderna have said they plan to present detailed results at an upcoming international medical meeting and engage with regulatory authorities about filing submissions.
Until regulatory review is completed, access to intismeran is generally through clinical trials rather than routine melanoma care.
What did earlier clinical trials show?
The Phase 3 results build on encouraging findings from the earlier Phase 2b KEYNOTE-942 study.
At five years of follow-up, intismeran plus Keytruda reduced the risk of recurrence or death by 49% compared with Keytruda alone in patients with high-risk stage III or IV melanoma that had been completely removed.
The combination also reduced the risk of distant metastasis or death by 59% compared with Keytruda alone.
Those earlier findings helped support the larger Phase 3 study. Importantly, the companies have not yet publicly reported the corresponding percentage reductions from INTerpath-001, so the Phase 2b numbers should not be presented as the Phase 3 results.
What do we know about side effects?
Merck and Moderna reported that the safety profiles of intismeran and Keytruda in INTerpath-001 were consistent with what had been observed in previous studies of the combination, with no new safety signals identified at the interim analysis.
However, detailed Phase 3 safety results have not yet been publicly presented.
Keytruda can cause immune-related side effects because activating the immune system can sometimes cause it to attack healthy organs and tissues. The risks and benefits of treatment should be discussed with the patient's oncology team.
More detailed Phase 3 results will be important for understanding the frequency and severity of side effects associated with the combination.
Could intismeran change melanoma treatment?
The positive Phase 3 results are significant because they represent the first successful Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy.
If detailed results continue to support the therapy's benefits and safety and the combination receives regulatory approval, personalized mRNA therapy could become a new approach to reducing recurrence after surgery for certain patients with high-risk melanoma.
The technology is also being studied in clinical trials involving other cancers, including non-small cell lung cancer, bladder cancer, and kidney cancer.
What happens next for intismeran and Keytruda?
INTerpath-001 will continue to evaluate important secondary outcomes, including overall survival.
Merck and Moderna plan to present detailed Phase 3 results at an international medical meeting and discuss regulatory submissions with health authorities.
Until those data are available, several important questions remain. Researchers need to better understand the magnitude of the Phase 3 benefit, longer-term overall survival, detailed safety results, and which patients may benefit most.
What should melanoma patients know about this trial?
For melanoma patients, the INTerpath-001 results are encouraging, particularly because preventing recurrence remains an important goal after surgery for high-risk melanoma.
However, patients should not change their current treatment based on a news announcement. Intismeran is still investigational, and established melanoma treatments remain available for patients who need therapy now.
If you have stage IIB, IIC, III, or resected stage IV melanoma, talk with your melanoma specialist about your individual recurrence risk, current adjuvant treatment options, and whether participation in a clinical trial may be appropriate.
Life after melanoma treatment and the risk of recurrence
Life after treatment can include regular follow-up appointments, skin examinations, imaging in some patients, and monitoring for signs that melanoma has returned.
Follow-up recommendations depend on melanoma stage, previous treatments, and individual risk factors. Patients should also continue checking their skin and report new or changing areas of skin, including a new or changing mole, to their healthcare team.
For patients at high risk of recurrence, advances in adjuvant therapy are intended to increase the chance that melanoma does not return after successful surgery.
What the Phase 3 results mean right now
The Phase 3 INTerpath-001 trial marks an important development in personalized cancer treatment. Intismeran autogene plus Keytruda significantly improved recurrence-free survival and distant metastasis-free survival compared with Keytruda alone in patients with completely resected high-risk stage IIB-IV cutaneous melanoma.
The results are promising, but intismeran is not yet an approved melanoma therapy. Detailed Phase 3 efficacy and safety data, regulatory review, and continued follow-up will provide a clearer picture of the combination's potential role in melanoma care.
For now, patients should continue following their recommended treatment and surveillance plans and talk with their healthcare team about current treatment options and appropriate clinical trials.
